AVITA MED LTD/S (NASDAQ:RCEL) Raised to “Buy” at ValuEngine
Several other research firms have also recently weighed in on RCEL. BTIG Research restated a buy rating and set a $8.00 price target on shares of AVITA MED LTD/S in a report on Thursday, June 18th. Oppenheimer initiated coverage on shares of AVITA MED LTD/S in a report on Monday, June 15th. They set a buy rating and a $9.00 price target on the stock. Lake Street Capital restated a buy rating and set a $12.00 price target on shares of AVITA MED LTD/S in a report on Thursday, March 5th. Finally, Zacks Investment Research cut shares of AVITA MED LTD/S from a buy rating to a hold rating in a research note on Tuesday, June 23rd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $8.88.
NASDAQ:RCEL opened at $6.09 on Friday. AVITA MED LTD/S has a one year low of $5.20 and a one year high of $55.35. The company has a market cap of $560.32 million, a PE ratio of -15.62 and a beta of 1.23. The firm has a 50-day moving average of $6.19 and a 200-day moving average of $7.40. The company has a debt-to-equity ratio of 0.03, a current ratio of 15.36 and a quick ratio of 15.22.
AVITA MED LTD/S Company Profile
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin.
Featured Article: What is a conference call?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for AVITA MED LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA MED LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.